Haddii aad qaadatid daroogada hormoonka tayroodhka ee hormoonada ah ee Synthroid, waxaad maqli kartaa dacwada dacwada fasalka oo laga soo horjeeday dawooyinka daroogada ee Knoll Pharmaceuticals, iyo shirkadda waalidka ee BASF, dhammaadkii 1990maadkii. Dacwadaas ayaa la dejiyey, laakiin waa muhiim in la ogaado waxa ku saabsan, iyada oo qayb ka ah taariikhda daroogada ugu sareysa ee iibka ah ee la yiraahdo levothyroxine.
Taariikhda Kale
Sanadkii 1990-yadii, Synthroid waxaa soo saaray khabiir Knoll. Synthroid waxay sheegtey 85% suuqyada levothyroxine sida 1997. Shirkadda Synthroid waxay si joogto ah uga qiimeeyeen tartamayaasheeda, wakiillada iibka daroogada iyo suugaanta suuqgeynta waxay sheegteen in qiimaha sare uu ahaa mid ku habboon sida daroogadu ka fiicnayd tartamayaasheeda. Shirkadda ayaa ku dhawaaqday in ay caddaynayso cilmibaarista iyo samaynta daraasad si ay u muujiso in Synthroid ay dhab ahaantii caafimaad ahaanba ka fiicantahay daawooyinka kale ee la midka ah iyo dawooyinka levothyroxine ee guud.
Daraasada, oo ay fulisay Betty Dong, MD, waxay ogaatay in Synthroid uu u dhigmaa, laakiin maaha mid ka sarreeya, daawooyinka tartiib tartiib tartiib ah. Markay taasi dhacdo, Sawirku wuxuu jiiday daraasaddan wuxuuna joojiyay daabacadii natiijooyinka joornaalada caafimaadka. Diidmadii Profoll, Dr. Dong ugu dambeyntii wuxuu ahaa daraasad la daabacay.
Ka dib markii la daabacay cilmi-baaristii Dr. Dong, dacwadaha dacwada fasalka waxaa loo gudbiyay iyaga oo ka wakiil ah macaamiisha kuwaas oo la rumaysan yahay in la marin habaabiyey inay bixiyaan wax badan oo ku saabsan Synthroid.
Ficilka fasalka waxaa la dejiyey 2000, waxaana lacagihii ugu dambeeyay ee macaamiisha la sameeyey sannadkii 2003. (Fiiro gaar ah: Isticmaalayaasha aan soo dirin wakhtigaas ma soo celin karaan lacag.)
Aasaasiga Dacwada Fasalka Hawlgabka
Dacwadda ayaa keentay baadhitaan, oo bilaabay 1996, oo lagu eedeeyay in shirkadda Knoll Pharmaceuticals iyo shirkadda waalidka ee BASF ay ku xadgudubtay sharciyada ilaalinta macaamiisha iyaga oo isku dayey in ay ka hortagaan daabacaadda natiijooyinka Dr. Dong ee cilmi baadhista cilmi-baarista, oo si cad u muujisay in magaca caanka ah ee guud iyo tartanka daawooyinka levothyroxine waxay u dhigantaa nooca Synthroid marka la eego waxtarka iyo nabadgelyada bukaannada tirakoobka.
Dr. Dong ayaa u sheegay Jariidada Ururka Caafimaadka Maraykanka in Daraasaddan la joojiyay muddo lix sano ah shirkadda daroogada. Knoll ayaa sidoo kale tixgeliyay in dacwad loo soo saaro daabacaadda si loo joojiyo daabacaadda daraasadda.
Dacwadda lagu soo oogay in eedaysanayaashu ay qarinayaan ama xakameynayaan macluumaadka ku saabsan magaca caanka ah ee la yiraahdo dabiiciga ah ee loo yaqaan 'biodegrad name drug and drug generator levothyroxine', ayaa si been abuur ah u muujisay in aysan jirin wax u dhigma Synthroid , sidaas awgeed macaamiisha ayaa ka badan intii ay bixin lahaayeen haddii ay ogaadeen in ay qaali ka qaali beddelaad.
Heshiiska Nidaamka Sharciga ee Qaybta Synthroid
Qodobka ugu horreeya ee ka dhanka ah Knoll waxaa lagu qiimeeyay ilaa $ 8.5 bilyan. Waqtigaas 2000, suuqyada levothyroxine waxaa lagu qiyaasay $ 600 million sanadkii. Heshiiskaas, si kastaba ha ahaatee, ayaa loo sameeyey si ka yar intii lagu jiray dacwadaha la raadinayo.
Talaadadii, August 8, 2000, Shirkadda Pharmaceutical Knup ayaa ku dhawaaqday in Garsoore Elaine Bucklo oo ka tirsan Maxkamadda Degmada Mareykanka ee Degmada Northland ee Illinois ay siisay markii ugu danbeysay ee ansixinta Heshiiska Falalka Sharciga ee Synthroid.
Dakhliga ka soo gala xisaabin asaasi ah, oo ah juun 30, 2000, wuxuu kudhawaadaa qiyaastii $ 91 milyan oo dulsaar ah (khidmadda qareenka iyo kharashka yar) ayaa loo qoondeeyey in la siiyo macaamiisha kuwaas oo dacwad ku soo oogay iyada oo la isku raacay in la sii daayo dhammaan sheegashooyinka ka dhanka ah Knoll.
Qadarka guud ee qiyaastii $ 46 milyan oo dulsaar iyo dulsaar ah (kharashka iyo kharashka qareenka yaraa) ayaa la siin lahaa xubnaha fasalka saddexaad ee bixiyaha.
Waqtigaas, Knoll ayaa ku qiyaasay in 778,000 macaamiisha ay heli doonaan lacag dhan $ 111 kasta haddii ay bilaabeen inay qaataan Synthroid ka hor Jannaayo 1, 1995, iyo qiyaastii $ 74 mid kasta oo ay bilaabeen inay qaataan Synthroid kadib Jeenawari 1, 1995. lacag bixinta ayaa la filayay in la diro ka hor dhamaadka sanadka 2000 haddii aan cabasho loo gudbin. Si kastaba ha ahaatee, rafcaannada ayaa la xareeyay, si kastaba ha ahaatee, degsiimooyinka ayaa dib u dhacay.
Ugu dambeyntii, jeega ugu dambeyntii waxaa loo direy bukaannada xilliga dayrta ee 2003. Waqtigaas, shabakada internetka ee loogu tala galay bixinta macluumaadka ku saabsan dacwadda iyo dejinta waxaa la joojiyey oo la xiray.
Ereyga ka
Dacwada ka dhanka ah shirkadda Synthroid ee loo yaqaan Knoll Pharmaceuticals iyo shirkadda waalidka BASF weligeed ma ahan oo ku saabsan ammaanka ama waxtarka Synthroid. Daroogada ayaa had iyo jeer loo tixgeliyaa amaan iyo waxtar. Dacwadda ayaa waxay ku adkaysanaysaa sheegashada suuq-geynta ee Synthroid-brand levothyroxine in uu kiliin ahaan ka sareeyay noocyada kale ee levothyroxine, iyo xaqiiqda ah in shirkaddu ay lacag badan ku bixisay Synthroid iyadoo lagu saleynayo qashinkaas khaldan.